Hacke W. et al. - Transcranial photobiomodulation in acute ischemic stroke: the NEST-3 Phase III randomized trial

This Phase III trial was terminated due to futility: transcranial laser therapy produced no measurable benefit following an acute ischemic stroke. The authors conclude that there is no neuroprotective effect when light is applied within 24 hours of symptom onset.

What this trial measured

NEST-3 is a randomized, double-blind, sham-controlled trial conducted in patients with acute ischemic stroke who were treated within 24 hours of symptom onset and who had not received thrombolysis. The study aimed to enroll 1,000 patients.

The primary endpoint was functional outcome at 90 days, assessed using the modified Rankin scale, with a hierarchical Bayesian analysis incorporating prior data. Two interim analyses were planned, after 300 and then 600 patients had been enrolled. The protocol was based on Phase II trials that were deemed encouraging.

Key Findings

The result is negative. The trial was halted on the recommendation of the independent data monitoring committee, following a futility analysis involving 566 patients.

• Good functional prognosis, modified Rankin scale score of 0 to 2: 140 of 282 patients (49.6%) in the transcranial laser group versus 140 of 284 (49.3%) in the sham procedure group.
• No difference was observed in the primary endpoint during the futility analysis.
• Results remained stable after including the 630 randomized patients: an adjusted odds ratio of 1.024 (95% CI 0.705 to 1.488), a range that largely encompasses the null hypothesis.
• The authors' conclusion: no measurable neuroprotective effect was observed for this indication and within this time frame.

Once the interim analysis results were known, the venture capital firms backing PhotoThera withdrew all support, and the company was dissolved. It was difficult to properly conclude the trial. It is registered under the identifier NCT01120301.

How photobiomodulation works for this indication

The hypothesis being tested was neuroprotective: near-infrared light applied through the skull was thought to support the energy metabolism of damaged brain tissue, thereby limiting the extent of the lesions. This hypothesis was not confirmed. The abstract does not allow us to distinguish between several possible explanations: absence of a biological effect, insufficient light penetration, a 24-hour delay that was too late, or inappropriate parameters. None of these factors are measured here.

Limits You Should Know

The primary limitation is the result itself: a failure to meet the primary endpoint in a properly designed Phase III trial that was terminated early due to futility. This finding remains unchanged.

The early termination reduced the sample size: 630 randomized patients instead of the planned 1,000. This does not invalidate the conclusion: futility means that a positive outcome had become unlikely. The scope of the study remains narrow: the trial focuses on acute ischemic stroke treated within 24 hours, without thrombolysis. It says nothing about other indications or the recovery phase following a stroke. Its implications are also methodological: a promising signal in Phase II may not be confirmed in Phase III. Finally, this trial dates from 2014, and more recent studies exist for other indications.

What This Means in Practice

Transcranial photobiomodulation should not be considered as a treatment for ischemic stroke in the acute phase: this is the direct and unambiguous finding of this trial. A stroke is a life-threatening emergency, and the only appropriate response is to call emergency services. No light-based device can replace this or should delay access to emergency care.

Frequently Asked Questions

Does photobiomodulation work after a stroke?

In this Phase III trial, no. NEST-3 was terminated due to futility and showed no difference in 90-day outcomes: 49.6% favorable outcomes with treatment versus 49.3% with sham procedure (adjusted odds ratio 1.024; 95% CI 0.705 to 1.488). The authors conclude that there is no neuroprotective effect.

What does a dismissal for lack of merit mean?

This refers to the termination of a trial when an interim analysis shows that a positive result has become highly unlikely, even if the trial were to continue to completion. In this case, the independent data monitoring committee recommended termination after reviewing data from 566 patients.

Does this negative result rule out photobiomodulation entirely?

No, and this point deserves clarification. The trial focuses on a single indication—acute ischemic stroke treated within 24 hours—and does not evaluate other uses. It does, however, show that a favorable result in a Phase II trial may not hold up in a large-scale trial, a finding that applies to the entire field.

Reference

Hacke W, Schellinger PD, Albers GW, et al. Transcranial laser therapy in the treatment of acute stroke: results of the Neurothera Effectiveness and Safety Trial 3, a Phase III clinical endpoint device trial. Stroke, 2014. PMID 25293665. View the study on PubMed

This summary is provided for informational purposes only and does not constitute medical advice. Photobiomodulation is not a substitute for prescribed treatment. Consult a healthcare professional.